ABSTRACT
Impaired lung function in early life is associated with the subsequent development of chronic respiratory disease. Most genetic associations with lung function have been identified in adults of European descent and therefore may not represent those most relevant to pediatric populations and populations of different ancestries. In this study, we performed genome-wide association analyses of lung function in a multiethnic cohort of children (n=1035) living in low-income urban neighborhoods. We identified one novel locus at the TDRD9 gene in chromosome 14q32.33 associated with percent predicted forced expiratory volume in one second (FEV1) (p=2.4×10-9; βz= −0.31, 95% CI= −0.41- −0.21). Mendelian randomization and mediation analyses revealed that this genetic effect on FEV1 was partially mediated by DNA methylation levels at this locus in airway epithelial cells, which were also associated with environmental tobacco smoke exposure (p=0.015). Promoter-enhancer interactions in airway epithelial cells revealed chromatin interaction loops between FEV1-associated variants in TDRD9 and the promoter region of the PPP1R13B gene, a stimulator of p53-mediated apoptosis. Expression of PPP1R13B in airway epithelial cells was significantly associated the FEV1 risk alleles (p=1.26×10-5; β=0.12, 95% CI=0.06-017). These combined results highlight a potential novel mechanism for reduced lung function in urban youth resulting from both genetics and smoking exposure.
AUTHOR SUMMARY Lung function is determined by both genetic and environmental factors. Impairment of lung function can result from harmful environmental exposures in early life, which disproportionally affect children living in low-income, urban communities. However, most genetic association studies of lung function have been performed in adults and without regard for socioeconomic status. Therefore, genetic risk factors discovered to date may not reflect those most relevant to high-risk populations. In this study, we sought to identify genetic variants correlated with lung function in a multiethnic cohort of children living in low-income, urban neighborhoods and analyze how tobacco smoke exposure may influence any genetic effects. We discovered a common genetic variant associated with lower lung function in this population, and we found that the association was mediated by nearby epigenetic changes in DNA methylation, which were in turn correlated with smoking exposure. We then identified a nearby gene, PPP1R13B, which is known to aid in the deactivation of damaged cells, whose expression in airway cells aligned with these genetic and epigenetic effects. This study reveals a potential mechanism through which genetic risk and environmental exposures can affect airway development, perhaps leading to interventions that can help reduce the burden of asthma in socioeconomically disadvantaged children.
Competing Interest Statement
All authors, with the exception of M. Altman and P. Becker, report grants from NIH/NIAID during the conduct of study. M. Dapas, C. Visness, A. Calatroni and P. Becker have nothing to disclose outside the submitted work. C. Ober reports personal fees from American Association of Asthma, Allergy and Immunology, outside the submitted work. M. Altman reports personal fees from Sanofi-Regeneron outside the submitted work. W. Busse reports personal fees from Boston Scientific, Novartis, Glaxo SmithKline, Genentech, Sanofi/Genzyme, AstraZeneca, Teva, Regeneron and Elsevier outside the submitted work. M. Gill reports an honorarium for and support for travel to the 2017 AAAAI meeting during the conduct of study and monetary compensation from the American Academy of Pediatrics for her work teaching the biannual Pediatrics board review course, PREP The Course. K. Hershey reports grants from Adare, during the conduct of the study. D. Jackson reports personal fees from Novartis, Boehringer Ingelheim, Pfizer, Regeneron, AstraZeneca, Sanofi and Vifor Pharma, grants and personal fees from GlaxoSmithKline and grants from NIH/NHLBI, outside the submitted work. M. Kattan reports personal fees from Regeneron, outside the submitted work. R. Gruchalla reports government employment from Center for Biologics Evaluation and Research as well as personal fees from Consulting Massachusetts Medical Society, outside the submitted work. A. Liu reports personal fees from Phadia ThermoFisher as consulting honoraria, grants and non-financial support from ResMed/Propeller Health, non-financial support from Revenio, grants and personal fees from Avillion and personal fees from Labcorp, outside the submitted work. L. Bacharier reports personal fees from GlaxoSmithKline, Genentech/Novartis, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi/Regeneron, Vectura and Circassia and personal fees and non-financial support from Merck outside the submitted work. J. Gern reports personal fees from AstraZeneca and Gossamer Bio and personal fees and stock options from Meissa Vaccines Inc, outside the submitted work. In addition, Dr. Gern has a patent Methods of Propagating Rhinovirus C in Previously Unsusceptible Cell Lines issued, and a patent Adapted Rhinovirus C issued. G. O'Connor reports personal fees from AstraZeneca and grants from Janssen Pharmaceuticals, outside the submitted work. R. Wood reports grants from DBV, Aimmune, Astellas, HAL-Allergy and Regeneron and royalties from Up to Date, outsite the submitted work. Dr. Becker's co-authorship of this publication does not necessarily constitute endorsement by the National Institute of Allergy and Infectious Diseases, the National Institutes of Health or any other agency of the United States government.
Funding Statement
This work was supported by NIH grants U19 AI62310, HHSN272200900052C, HHSN272201000052I, UM1 AI114271, UG3 OD023282, and UM1 AI160040. Site data collection was supported by the following NIH grants: RR00052, UL1 TR001079 (Baltimore); M01 RR00533, UL1 RR025771, 1 UL1 TR001430 (Boston); UL1 TR000150 (Chicago); UL1 TR000451, UL1 TR001105 (Dallas); Ul1 RR025780 (Denver); UL1 TR000040, M01 RR00071, UL1 RR024156 (New York); UL1 TR000075 (D.C.); UL1 TR000077 (Cincinnati). M.D. was supported by TL1 TR002388 and T32 HL007605.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The institutional review boards (IRBs) from all participating sites of the Urban Environmental Factors and Childhood Asthma (URECA, ClinicalTrials.gov Identifier: NCT00114881) and Asthma Phenotypes in the Inner City (APIC, ClinicalTrials.gov Identifier: NCT01383941) studies gave initial ethical approval for this work. These include IRBs from the following institutions: National Jewish Health, Denver, CO (APIC); Children's National Medical Center, Washington, DC (APIC); Children's Memorial Hospital, Chicago, IL (APIC); Johns Hopkins University, Baltimore, MD (APIC & URECA); Boston University School of Medicine, Boston, MA (APIC); Henry Ford Health Center, Detroit, MI (APIC); Columbia University Medical Center, New York, NY (APIC & URECA); Cincinnati Children's Hospital, Cincinnati, OH (APIC); University of Texas Southwestern Medical School, Dallas, TX (APIC); Boston Medical Center, Boston, MA (URECA); Saint Louis Children's Hospital, Saint Louis, MO (URECA). In 2014, ethical oversight for these studies transitioned to a single, central IRB managed by WGC IRB (formerly Western IRB), whereupon WGC IRB gave ethical approval for this work. Written informed consent was obtained from legal guardians of all participating children, who also assented.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
major revision featuring genetic heterogeneity analysis and more robust investigation into potential bias affecting the MR and mediation analyses
Data Availability
Phenotype, genotype, GWAS summary statistics, and whole-genome sequencing files are available in dbGaP under accession phs002921.v1.p1. The URECA gene expression data are available on the Gene Expression Omnibus (GEO) under the accession GSE145505 (NECs) and GSE96783 (PBMCs). The pcHI-C data are available in GEO under the reference series GSE152550. The DNA methylation data will be deposited to GEO (Morin, et al. A Functional Genomics Pipeline to Identify High-Value Asthma and Allergy CpGs in the Human Methylome. medRxiv. 2022:2022.05.19.22275204).
https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002921.v1.p1
